Tavotek Biotherapeutics
United States
- Lower Gwynedd, PA
- 18/11/2021
- Series B
- $35,000,000
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.
- Industry Pharmaceutical Manufacturing
- Website https://www.tavotek.com/
- LinkedIn https://www.linkedin.com/company/tavotek/
Related People
Di ZhangFounder
United States -
Ambler, Pennsylvania
Executive scientific leader with over 20 years drug discovery research experience in the biotechnology and pharmaceutical industries. Dynamic entrepreneur with experiences of building R&D capabilities from scratch for start-up biotech companies. Seasoned drug developer in the fields of antibody based biotherapeutics, gene editing and cell therapy, and small molecule drugs. Proud achiever with the development of two antibody drugs in clinical trial and multiple oncology drugs in preclinical development. Lead authors and inventors for dozens of research publications and patent applications.
Slate Medicines | $130,000,000 | (Feb 25, 2026)
Letter AI | $40,000,000 | (Feb 25, 2026)
Subject | $28,000,000 | (Feb 25, 2026)
Centauri Therapeutics Limited | $8,107,170 | (Feb 25, 2026)
Slang AI | $36,000,000 | (Feb 25, 2026)
Brilliant Harvest Inc. | $4,000,000 | (Feb 25, 2026)
Koah | $20,500,000 | (Feb 25, 2026)
Nimble | $47,000,000 | (Feb 25, 2026)
General Magic | $7,200,000 | (Feb 25, 2026)
Circadian Risk Inc. | $6,000,000 | (Feb 25, 2026)
Neural Earth | $9,300,000 | (Feb 25, 2026)
Jampack AI | $3,200,000 | (Feb 25, 2026)